Clinical trials: Body Weight
Obesity
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.
- Trial name
- NCT00131404
- Testing
- taranabant
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Obesity
A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body
The primary objective of this trial is to assess bioequivalence of two formulations of survodutide (formulation A and formulation B6) after multiple-dose treatment in male and female trial participants living with overweight or…
- Conditions
- Healthy, Obesity, Overweight
- Trial name
- NCT07407348
- Testing
- Formulation A, Formulation B6
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cachexia
Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects
The purpose is to evaluate the safety, tolerability, and PK of NGM120 in healthy adult subjects
- Trial name
- NCT03392116
- Testing
- NGM120
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- NGM Biopharmaceuticals, Inc
Overweight , Obesity
A Study of SRSD384 in Overweight or Obese Participants
This is a two-part study, intended to investigate the safety, tolerability, characteristics of PK and PD of single SC dose of SRSD384 alone in overweight or obese participants (Part A) and in combination with tirzepatide in…
- Trial name
- NCT07557355
- Testing
- SRSD384 injection
- Where
- Australia
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Sirius Therapeutics Co., Ltd.
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight
This trial is conducted in The United States of America. The aim of this trial is to investigate Safety, Tolerability, Pharmacokinetics (the exposure of the trial drug in the body) and Pharmacodynamics (the effect of the…
- Trial name
- NCT02958085
- Testing
- NNC0174-0833
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity.
- Trial name
- NCT06717425
- Testing
- PF-07976016
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Obesity
Vagal Blocking for Obesity Control
To determine the safety, efficacy and treatment algorithm(s) of the Maestro System in causing weight loss in obese subjects - This study will provide feasibility data regarding the potential of intra-abdominal vagus nerve…
- Trial name
- NCT00555958
- Testing
- Active, implantable, intra-abdominal vagal blocking medical device
- Where
- 5 sites in Australia, Mexico and 2 more
- Volunteers
- 120 people
- Sponsor
- ReShape Lifesciences
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
Taldefgrobep Alfa in Adults With Overweight and Obesity
This is a multicenter, randomized, double-blind, placebo-controlled, multiple dose study to evaluate the efficacy, safety, and tolerability of taldefgrobep alfa in adults with overweight and obesity, with an open-label extension.
- Trial name
- NCT07281495
- Testing
- Taldefgrobep Alfa
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- Biohaven Therapeutics Ltd.
Obesity
Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball
This study was conducted to compare the effectiveness of two local pain control methods in bariatric patients by assessing the amount of postoperative pain and amount of postoperative pain medications needed.
- Trial name
- NCT02142829
- Testing
- EXPAREL, On-Q Pain Ball
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Obesity in Diabetes, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM
This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo.
- Trial name
- VESPER-2 (NCT06897202)
- Testing
- MET097 Injection
- Where
- 29 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pfizer
Obesity, Abdominal Obesity
Study of Safety and Efficacy of a Probiotic and Postbiotic in Overweight Individuals
Investigate the effect of a probiotic (live bacteria) and postbiotic (heat-treated bacteria) strains in overweight individuals.
- Trial name
- KOBI (NCT05428137)
- Testing
- Probiotic, Postbiotic
- Where
- South Korea
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Obesity, Overweight
THE ENLIGHTEN STUDY
The primary objective of this study is to demonstrate the safety and efficacy of the Elipse Gastric Balloon System for the treatment of obese adults.
- Trial name
- NCT03261453
- Testing
- Active Elipse Device
- Where
- 12 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allurion Technologies
Overweight , Obesity
Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight
This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants.
- Trial name
- NCT07791537
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Cachexia, Pancreatic Neoplasms
A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Pancreatic Cancer Related Cachexia
The purpose of this study is to evaluate the effectiveness and safety of infliximab, the active ingredient in Remicade, for the treatment of cachexia in pancreatic cancer patients who are receiving chemotherapy with gemcitabine.
- Trial name
- NCT00060502
- Testing
- Infliximab; Gemcitabine
- Volunteers
- 73 people
- Sponsor
- Centocor, Inc.
Obesity, Morbid Obesity
Study of Weight Loss Using Gastric Stimulation in Obese Patients
The purpose of this study is to test the effect of an implanted device that stimulates the stomach to help obese patients lose weight.
- Trial name
- SHAPE (NCT00200083)
- Testing
- Transcend II Model 8848
- Where
- 8 sites in United States
- Volunteers
- 190 people
- Sponsor
- MedtronicNeuro
Infant Development
Effect of a New Infant Cereal on Weight Gain
The purpose of this study is to determine whether a new infant cereal has an effect on weight gain and intestinal microbiota compared to a standard cereal in healthy infants .
- Trial name
- CEOBE (NCT02165956)
- Testing
- New Infant Cereal, Standard Infant Cereal
- Where
- 5 sites in Spain
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Laboratorios Ordesa
Cachexia
SUN11031 in Cachexia Associated With Chronic Obstructive Pulmonary Disease (COPD)
To evaluate SUN11031 for subcutaneous injection compared to placebo in subjects with cachexia associated with Chronic Obstructive Pulmonary Disease (COPD) to determine the effect on physical performance and body composition.
- Trial name
- NCT00698828
- Testing
- SUN11031 20 μg/kg, SUN11031 40 μg/kg
- Where
- 43 sites in United States, Argentina and 4 more
- Volunteers
- 227 people
- Sponsor
- Daiichi Sankyo
Overweight, Obesity
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity.
- Trial name
- NCT05548231
- Testing
- LY3437943
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Obesity
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity
This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without…
- Trial name
- NCT03842501
- Testing
- Release Supplement
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Golo